compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. We may also receive compensation if you click on certain links posted on our site. We may receive compensation from our partners for placement of their products or services. While we are independent, the offers that appear on this site are from companies from which receives compensation. and changed its name to RAPT Therapeutics, Inc.į is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
What is rapt trial#
Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. This would suggest that RAPT Therapeutics's shares are less volatile than average (for this exchange). The market (NASDAQ average) beta is 1, while RAPT Therapeutics's is 0.1262. A popular way to gauge a stock's volatility is its "beta".īeta is a measure of a share's volatility in relation to the market. Over the last 12 months, RAPT Therapeutics's shares have ranged in value from as little as $14.89 up to $43.26. We're not expecting RAPT Therapeutics to pay a dividend over the next 12 months. TTM: trailing 12 months RAPT Therapeutics share dividends We chose Tradier for this because it offers a wealth of tools and data for active traders, including the ability to use its data and create a custom trading platform. You can search for stocks by company name, and the mobile app is clean and intuitive to use. We chose Robinhood for this category because it offers commission-free trading and is easy to use. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
What is rapt free#
We chose SoFi for this category because it offers a free robo-advisor as well as commission-free stocks. We encourage you to compare stock platforms to find one that's best for your particular budget and goals. We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs.
0 kommentar(er)
